A 52‐week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity

Lomenick, Jefferson P.; Buchowski, Maciej S.; Shoemaker, Ashley H.

doi:10.1002/oby.21493

Cited by 47 publications

(45 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several trials have analyzed the effects of antidiabetic agents on weight development in patients with HO [74][75][76][77][78][79][80][81][82] (Table 2). Zoicas et al [78] analyzed the effect of treatment with GLP-1 receptor agonist on weight development in 8 patients (6 CP) with HO.…”

Section: Pharmacological Treatment Of Homentioning

confidence: 99%

The Diagnosis and Treatment of Craniopharyngioma

Müller

2019

Neuroendocrinology

108

View full text Add to dashboard Cite

Craniopharyngioma (CP) is a rare embryonic malformation of the sellar/parasellar region with a low histological grade. Clinical manifestations are related to hypothalamic/pituitary deficiencies, visual impairment, and increased intracranial pressure. Recent insight into the molecular pathogenesis of CP opens new perspectives on targeted therapy in papillary CP harboring BRAF-V600E mutations. Further research to elucidate pathogenic mechanisms and hopefully prevent hypothalamic involvement of CP is warranted. If the tumor is favorably localized, the therapy of choice is complete resection, with care taken to preserve the optical and hypothalamic functions. In patients with unfavorable tumor localization (i.e., hypothalamic involvement), the recommended therapy is a limited hypothalamus-sparing surgical strategy followed by local irradiation. Surgical treatment strategies should be based on a multidisciplinary approach involving experienced teams. Centralizing the treatment of CP in experienced "centers of excellence" and multicenter-based networks for reference assessments should be considered to assure a high standard of treatment quality. CP recurrence and progression are frequent. Irradiation has proven effective in reducing recurrences and progression. Proton beam therapy, available in a wider range in the near future, will help to avoid radiooncological side effects. Anatomical involvement and/or surgical lesions of posterior hypothalamic areas can result in serious sequelae that compromise quality of life (QoL), such as hypothalamic obesity and psychopathological symptoms. Novel insights into neuropsychological sequelae after CP occurrence should be the basis for the development of therapeutic neuropsychological interventions. CP should be managed as a frequently chronic disease, providing ongoing care of pediatric and adult patients' clinical and QoL consequences by experienced multidisciplinary teams.

show abstract

Section: Pharmacological Treatment Of Homentioning

confidence: 99%

The Diagnosis and Treatment of Craniopharyngioma

Müller

2019

Neuroendocrinology

108

View full text Add to dashboard Cite

show abstract

“…These physical factors should also be considered when “prescribing” a practical and achievable exercise plan for a CP patient. It is possible for CP patients with HO to achieve some weight loss with pharmacologic therapy, summarized in Table . Tumoural or surgical damage to hypothalamic nuclei may compromise the efficacy of agents that act centrally, such as recombinant leptin or the appetite‐suppression effects of glucagon‐like peptide .…”

Section: Obesitymentioning

confidence: 99%

Management of hypothalamic disease in patients with craniopharyngioma

Thompson

Costello

Crowley

2019

Clinical Endocrinology

View full text Add to dashboard Cite

Patients with craniopharyngioma experience excess morbidity and mortality when compared with the background population and with other hypopituitary patients.Large, suprasellar tumours which form micropapillae into surrounding structures can cause hypothalamic damage before any therapeutic intervention; attempted gross total resection can lead to hypothalamic obesity, sleep disorders, thirst disorders and dysregulation of temperature as well as panhypopituitarism. The management of tumour bulk and the pathophysiology of hypothalamic complications have been reviewed extensively. We present a practical, clinical approach to management of hypothalamic disease in a patient with craniopharyngioma and highlight potential targets for future pharmacological or surgical intervention. K E Y W O R D Scraniopharyngioma, hypopituitarism, hypothalamus, obesity, sleep disorders, thirst

show abstract

“…Therefore, multiple DPP4 inhibitors have been developed for treating type 2 diabetes [ 160 ]. Although various gliptins are known to be neutral on body weight in type 2 diabetic patients, the effect on body fat mass has not been fully elucidated in humans and animals yet [ 161 – 163 ]. However, recently it has been described that fat loss by the DPP4 inhibitor evogliptin, in contrast to exenatide, might likely be mediated by increased energy expenditure and alteration in white adipose tissue metabolism from obese mice [ 100 ].…”

Section: New Perspectives In the Treatment Of Obesitymentioning

confidence: 99%

Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications

Gómez-Hernández

Beneit

Díaz-Castroverde

et al. 2016

International Journal of Endocrinology

157

View full text Add to dashboard Cite

This review focuses on the contribution of white, brown, and perivascular adipose tissues to the pathophysiology of obesity and its associated metabolic and vascular complications. Weight gain in obesity generates excess of fat, usually visceral fat, and activates the inflammatory response in the adipocytes and then in other tissues such as liver. Therefore, low systemic inflammation responsible for insulin resistance contributes to atherosclerotic process. Furthermore, an inverse relationship between body mass index and brown adipose tissue activity has been described. For these reasons, in recent years, in order to combat obesity and its related complications, as a complement to conventional treatments, a new insight is focusing on the role of the thermogenic function of brown and perivascular adipose tissues as a promising therapy in humans. These lines of knowledge are focused on the design of new drugs, or other approaches, in order to increase the mass and/or activity of brown adipose tissue or the browning process of beige cells from white adipose tissue. These new treatments may contribute not only to reduce obesity but also to prevent highly prevalent complications such as type 2 diabetes and other vascular alterations, such as hypertension or atherosclerosis.

show abstract

A 52‐week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity

Cited by 47 publications

References 20 publications

The Diagnosis and Treatment of Craniopharyngioma

The Diagnosis and Treatment of Craniopharyngioma

Management of hypothalamic disease in patients with craniopharyngioma

Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications

Contact Info

Product

Resources

About